Friday, October 30, 2026

Enphase Energy Soars Over 33% In 21 Sessions - Is It Time To Invest?

ViaNews Editorial Team

December 26, 2023

Enphase Energy Soars Over 33% In 21 Sessions - Is It Time To Invest?

(VIANEWS) - Enphase Energy (NASDAQ: ENPH) shares have seen an incredible 33.7% gain over 21 sessions, increasing from EUR100.22 on November 24th to EUR133.99 as of 02:58 EST Tuesday at 02:58 ET, an astounding increase of 33.7%! Enphase Energy stock saw two consecutive gains at 02:58 EST while also driving up the NASDAQ by 0.19% to EUR14,992.97 after two sessions of gains for Enphase. Enphase's closing price on Tuesday stood at EUR133.99 which represents 54.27% below its 52 week high of EUR293.03

About Enphase Energy

Enphase Energy, Inc. is a premier provider of home energy solutions for the solar photovoltaic industry. They design, develop, manufacture and sell microinverters that convert energy at individual solar module level as well as monitoring and control services; energy storage solutions; electric vehicle charging solutions and design services are also offered as services to enhance solar installations. Enphase sells their products through distributors, large installers, original equipment Manufacturers (OEM), strategic partners as well as their online store with legacy product upgrade program for homeowners worldwide. Established in 2006 they are headquartered out of Fremont California

Yearly Analysis

Based on available information, Enphase Energy's stock is currently trading at EUR133.99; significantly less than its 52-week high of EUR293.03 yet higher than its 52-week low of EUR73.49. This indicates that Enphase Energy experienced a steep drop in value over the last year before seeing some rebound recently; nonetheless investors should keep this fact in mind before investing. Enphase Energy's expected sales growth for this year is negative 0.4%, suggesting revenues may decline this year and into next. Furthermore, next year's projected negative 16.2% sales growth could signal even greater reduction in revenues and cause concern among investors as this may negatively affect financial performance and ultimately the stock price. Enphase Energy's EBITDA currently stands at 6.56, which indicates a positive net income before accounting for interest, taxes, depreciation and amortization expenses. However, EBITDA should not be used as an alternative measure of profitability since it does not conform with GAAP accounting rules. Overall, investors in Enphase Energy should exercise caution due to its expected decrease in sales growth and its current value being below its 52-week high. However, positive EBITDA suggests the company is producing positive net income and could signal positive returns for investors. To make informed investment decisions it is recommended that further analysis be performed on Enphase Energy's financials as well as market conditions before making decisions relating to Enphase Energy investments.

Technical Analysis

Enphase Energy's stock price has been on an unpredictable path, currently trading at EUR125.88; above its 50-day moving average of EUR101.19 but below its 200-day moving average of EUR147.15. Last reported volume was 4,146,189; 25.51% lower than its average volume of 5,566,660 over time. Volatility over this past month has been relatively consistent, averaging 2.02% intraday variation average. According to stochastic oscillator analysis, Enphase Energy shares are currently considered oversold by this indicator - providing insight into overbought and oversold conditions.

Quarter Analysis

Investment Outlook: According to Enphase Energy's sales growth and revenue growth data for both this quarter and next, their performance appears to be declining and may not make for an attractive investment opportunity in the short-term. Negative growth estimates for both current and subsequent quarters suggest that performance will likely worsen further in the near future. Be mindful that this analysis only takes into account data provided, without taking into account other potential influences that could alter the performance and future prospects of a company. Thus, investors should conduct more thorough research and analysis before making investment decisions.

Equity Analysis

Enphase Energy, a leading provider of energy management solutions, recently reported strong financial performance with an EPS figure of EUR3.99 over its trailing twelve month period, showing it is making significant profits. Enphase Energy's trailing twelve month PE ratio of 33.58 indicates that investors are willing to pay a premium for its stock, reflecting confidence in Enphase's long-term growth potential. Enphase Energy's return on equity of 70.38% shows that they are effectively using shareholder's equity to generate profits, providing investors with assurances that Enphase Energy can deliver strong returns to them. This should give confidence to investors. Overall, Enphase Energy appears to be a financially secure company with strong profitability prospects; however, investors should also take into account other considerations like market trends and its growth potential before making any definitive investment decisions.

More news about Enphase Energy (ENPH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com